Skip to main content

FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma



Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no effective therapies for these patients.


Formalin fixed paraffin embedded (FFPE) samples of 556 GC patients, including 64 PC GC, were collected for next-generation sequencing (NGS). Clinical characteristics and genomic profiling were analyzed. FGFR2 expression was detected by quantitative real time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). FGFR2 inhibitors response was studied in vitro.


Among 556 GC patients, PC GC patients were younger (P = 0.004), had lower tumor mutation burden (TMB-L) (P = 0.001) than non-PC GC. The top 10 most frequently mutated genes in PC GC were TP53 (48%), CDH1 (31%), ARID1A (14%), FGFR2 (14%), ERBB2 (9%), CDKN2A (9%), FGF3 (8%), LRP1B (9%), FGF19 (8%) and FGF4 (8%). Noticeably, FGFR2 is more frequently mutated than non-PC GC (14% vs. 6%, P = 0.037), including copy number variants (CNVs, 12.5%) and gene rearrangements (3.1%, FGFR2/VTI1A and FGFR2/TACC2). Former studies have confirmed that gain of copy number could increase FGFR2 expression and sensitivity to FGFR2 inhibitors in GC. However, no research has verified the function of FGFR2 rearrangements in GC. Our results showed that cell lines of GC transfected with TACC2-FGFR2 fusion had increased mRNA and protein expression of FGFR2, and were more sensitive to FGFR2 inhibitors. FGFR2 inhibitors might be a new therapeutic target for PC GC. In addition, we found patients of PC GC harboring gene rearrangements (n = 9) had poorer overall survival (OS) in comparison with patients without any gene rearrangement (n = 19) (16.0 months vs 21.0 months, P = 0.043). Gene rearrangement might be an adverse prognostic factor for PC GC patients.


FGFR2 alterations were recurrent in PC GC and FGFR2 inhibitors might be a new therapeutic target for PC GC.


Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer mortality in the word [1]. Numerous studies have shown that GC is histologically and genetically heterogeneous. The WHO classified GC into papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly cohesive (PC) carcinoma, mixed adenocarcinoma and other rare subtypes [2]. In recent years, a decrease occurred in the overall incidence of GC, however, the proportion of GC with WHO PC histology is increasing [3]. PC GC is defined as tumor composed of isolated or small groups of tumor cells by the WHO classification [3]. Compared to other GC subtypes, PC GC is poorly differentiated and easy to metastasized. None of current treatments, including chemotherapy, radiotherapy, targeted therapy and immunotherapy, has shown good results [4, 5].

Although the histopathological classifications currently remain the most commonly used for therapy decision making in the clinical setting, molecular classifications have been developed to guide future treatment development [5]. Several different molecular GC classification systems have been proposed these years, attempting to relate molecular features to histological phenotypes and clinical features [6, 7]. In 2014, The Cancer Genome Atlas (TCGA) research network proposed four molecularly distinct GC subtypes: Epstein–Barr virus infected (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN) [8]. Also, in 2015, the Asian Cancer Research Group classified GC into four molecular subtypes: mesenchymal-like, microsatellite-unstable, the tumor protein 53 (TP53)-active and TP53-inactive types [9]. However, there are few detailed studies on the mutational spectrum of PC GC. Further investigation of the genetic alterations may provide useful information to explore new therapies for PC GC patients.

In this study, we compared the clinical characteristics and genomic profiling of PC GC patients and non-PC GC patients. Furthermore, we investigated whether genetic alterations are associated with patient prognosis in PC GC. Finally, we tried to seek new therapies according to specific genetic alterations of PC GC.


Patients and samples

We collected 556 patient samples of gastric adenocarcinoma. All histopathologic diagnoses were reviewed by at least two senior pathologists independently. Clinical information was retrospectively collected and the overall survival (OS) was measured from the date of surgery to the date of death or the last follow-up visit. The last follow-up date was August 8th, 2016. This study was conducted in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki) and approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2016-196-01).

Nucleic acid preparations and next-generation sequencing

Formalin fixed paraffin-embedded (FFPE) tissues obtained from patients with GC were collected for NGS in a 450-gene panel assay, whose accuracy has been verified before (Additional file 1: Figure S1). DNA was extracted from the unstained FFPE sections with tumor content of no less than 20% and was fragmented to ~ 250 bp by sonication. A library was constructed using the KAPA Hyper Prep Kit (KAPA Biosystems) and hybridization capture was performed with a custom panel containing individually synthesized 5ʹ-biotinylated DNA probes. The capture probes target exons of 450 cancer-related genes and frequently rearranged introns of 38 genes. Paired-end sequencing was performed according to the manufacturer’s protocols. Genomic alterations, including single base substitutions, short and long insertions/deletions (INDELs), copy number variations, and gene rearrangements, were assessed using the OrigiMed-pipeline. Genomic alterations relevant for cancer immunotherapy, which included TMB levels and MSI, were also evaluated [10, 11]. Mutation signature was predicted using a public software deconstuctSigs. All substitution mutations were classified into 96 kinds of trinucleotides and the frequency of each was precisely calculated as the characteristic signature of these samples. The signature was then compared with the typical 30 signatures from COSMIC to identify the most similar combination and the percentage of each contributed [12].

Cell lines

To verify the function of TACC2-FGFR2 fusion, we generated gastric cancer cell lines with stable expression of TACC2-FGFR2. The Lenti-EF1a-EGFP-pGK-Puro retroviral vectors containing the particular fusion genes were transfected into 293 T cells to produce virus. MKN45 and NUGC4 cells were then infected with the viral supernatant containing expression constructs. Stable transfectants were obtained and maintained under selection pressure by puromycin dihydrochloride (2 µg/ml, Beyotime, ST551-10 mg). Under selection conditions, clones were picked and maintained.

Quantitative real time polymerase chain reaction (qRT-PCR) analysis

Total RNAs were extracted by TRIzol™ Reagent (Thermo Fisher Scientific, 15596018), then dissolved in RNase-free water. cDNA synthesis is performed in the first step using total RNA, Random Primers (Thermo Fisher Scientific, 48190011) and dNTP Mix (10 mM ea, 18427013), 5 min at 65 °C. In the second step, PCR is performed in a separate tube using probes specific for the gene of interest, M-MLV Reverse Transcription (200 U/ul, 28025013) and RNase OUT™ Recombinant Ribonuclease Inhibitor (Thermo Fisher Scientific, 10777019), following the procedures of 10 min at 25 °C, 45 min at 37 °C, 10 min at 70 °C, and then 4 °C. TaqMan™ Fast Advanced Master Mix (Thermo Fisher Scientific, 444556) was used with the following PCR parameters, 1 cycle of 20 s at 95 °C, 40 cycles of 1 s at 95 °C and 20 s at 60 °C using QuantStudio™ 7 Flex (Applied Biosystems). Probes used in this study are FGFR2 (Thermo Fisher Scientific, Hs01552918_m1) and β-actin (Thermo Fisher Scientific, Hs99999903_m1).

Immunohistochemical staining of tumor tissues

The expression of PD-1, PD-L1, CD3, FGFR2 in tumors was evaluated via immunohistochemical analysis (anti-PD-1, 1:100, NAT105, Cell Marque; anti-PD-L1, 1:100, SP142, Spring Bio; anti-CD3, 1:500, CD3-565-L-CE, Leica/Novocastra; anti-FGFR2, 1:200, ab58201, Abcam). The PD-1, PD-L1 is observable in the cytoplasm or on the membrane of the tumor cell or the TILs. The immunoreactivity of PD-1, PD-L1 was evaluated semiquantitatively according to the percentage and intensity of positive cells. Specimens in which PD-1 or PD-L1 were observed in more than 1% of tumor cells or immune cells were considered PD-1 or PD-L1 positive. CD3 was detected in the nuclei of the TILs. The distribution of CD3+ TILs was observed in the areas with the highest density of TILs first at low magnification. The amount of positive TILs was then recorded at high magnification (HPF 400× magnification). The number of CD3+ TILs was determined in 30 random high power fields in each section.

Fluorescence in situ hybridization (FISH)

Two-color FISH was performed on 2 µm thick sections from formalin-fixed, paraffin-embedded tumor tissues with FGFR2 rearrangements and paired normal tissues. Before hybridization, sections were deparaffinized, dehydrated in 100% ethanol, and air-dried. Commercially available, locus-specific FGFR2 probe (anbiping, F.01197-01) were used according to the manufacturer’s recommendations. 377-kb Spectrum Green directly labeled fluorescent DNA in the 3ʹ of FGFR2 and 446-kb Spectrum Red directly labeled fluorescent DNA in the 5ʹ of FGFR2.

Drug sensitivity test

Cell counting kit-8 (CCK-8) (Vazyme, A311-01/02) assay was used to estimate drug response. Briefly, 2500 cells were seeded each well of 96-well plates with 100 μl of 10% FBS 1640 medium, and treated with BGJ398 (Selleck, S2183), AZD4547 (Selleck, S2801) or Erdafitinib (Selleck, S8401) on the 2nd day. After additional days of incubation, 10 μl CCK-8 was added into each well and incubated for 2 h. Afterwards, absorbance was measured at 450 nm with microplate reader. The IC50 values were calculated with nonlinear regression analysis by using GraphPad.

Statistical analysis

Statistical analysis was performed by SPSS statistics software, version 25.0 (SPSS, Chicago, IL, USA). The continuous variables were tested for normal distribution before analyzing by t test. The categorical variables were taken with the Pearson’s Chi-square test (or Fisher’s exact test). Impact of clinical characteristics and genetic alterations on survival outcomes were estimated by using Kaplan–Meier method, Cox proportional hazard modeling. A two-tailed P value of less than 0.05 was regarded as statistically significant.


Clinical characteristics and genomic profiling of PC GC and non-PC GC patients

In this study, a total of 556 GC samples were included. Among all GC patients, 64 (11.5%) are diagnosed as PC GC and 492 (88.5%) are non-PC GC. We compared the clinical characteristics between PC GC and non-PC GC patients (Table 1). It showed that PC GC patients were younger than non-PC GC (proportion of patients younger than 60 years old was 65.6% vs. 46.3%, P = 0.004) (Table 1). Also, PC GC patients are more likely to be female, although there was no significant difference (proportion of female patients was 40.6% vs. 32.7%, P = 0.208) (Table 1).

Table 1 Clinical characteristics and genomic profiling of PC GC and non-PC GC patients (N = 556)

Formalin fixed paraffin-embedded (FFPE) tissues obtained from these 556 GC patients were collected for NGS in a 450-gene panel assay (Fig. 1a). Microsatellite instability (MSI) status was identified based on mismatch repair (MMR) gene expression, while tumor mutation burden (TMB) was defined as mutations per megabase (Muts/Mb). NGS analysis revealed all 64 gastric PC GC patients were MSS, while 29 (5.9%) non-PC GC patients were MSI-H (P = 0.085) (Table 1). Similarly, only 9.4% (6/64) PC GC patients had high TMB (≥ 10 Muts/Mb) while the proportion among non-PC GC patients was 28.3% (139/492) (P = 0.001) (Table 1).

Fig. 1
figure 1

a Overview of recurrent somatic genomic alterations in GC patients. The patient samples are shown on the x-axis. Information of mutation rate, MSI status, gender, and patient age are shown on the top of y-axis, followed by the key genetic alterations including significant mutated genes. Frequency of each alteration were illustrated on the left or right of the mutation heat plot. b Overview of gene rearrangements in 64 gastric PC GC patients. Each line connecting two genes represented one gene rearrangement, and each color represented one patient. In all, 13 gastric PC GC patients had gene rearrangements. Orange arrow indicated the patient who had two gene rearrangements and they overlapped each other

The top 10 most frequently mutated genes among 64 gastric PC GC patients were TP53 (48%), CDH1 (31%), ARID1A (14%), FGFR2 (14%), CDKN2A (9%), ERBB2 (9%), LRP1B (9%), FGF19 (8%), FGF3 (8%), and FGF4 (8%), compared to TP53 (66%), ARID1A (20%), LRP1B (16%), CDH1 (14%), PIK3CA (12%), FAT4 (10%), TGFBR2 (10%), KRAS (10%), APC (9%) and KMT2D (8%) in non-PC GC patients (Fig. 1a). Genomic alterations including single nucleotide variants (SNVs), INDELs, copy number variations (CNVs), gene fusions and rearrangements were assessed. We respectively compared the most frequent SNVs and INDELs, CNVs and rearrangements between PC GC and non-PC GC. SNVs and INDELs of TP53 (64.8% vs 46.9%, P = 0.005), CNVs of CCNE1 (12.4% vs 3.1%, P = 0.028) occurred more frequently in non-PC GC while SNVs and INDELs of CDH1 (12.6% vs 28.1%, P = 0.001), CNVs of FGFR2 (5.1% vs 12.5%, P = 0.037) occurred more frequently in PC GC (Table 1).

The value of gene rearrangements in predicting prognosis for PC GC

We detected gene rearrangements in 20.3% (13/64) PC GC patients (Fig. 1b). Specially, FGFR2 rearrangements (FGFR2/VTI1A and FGFR2/TACC2) were recurrently detected in 3.1% (2/64) PC GC tumor samples. We collected clinical characteristics and prognostic information of 28 PC GC patients from Drum Tower Hospital. It demonstrated that PC GC patients with gene rearrangements had a higher N stage (P = 0.001) and a higher tumor stage (P = 0.010) defined by 8th American Joint Committee on Cancer (AICC) criterion (Table 2). Moreover, patients harboring gene rearrangements (n = 9) had a shorter overall survival (OS) in comparison with patients without any gene rearrangement (n = 19) (16.0 months vs 21.0 months, P = 0.043) (Fig. 2a). To further explore the risk factors related to survival outcome of PC GC, we employed univariate and multivariate Cox regression analyses to identify protective or adverse prognostic factors. As shown in Additional file 1: Table S1, independent prognosis factors of PC GC identified in the univariate Cox regression are age over 60 years old (HR = 2.630, 95% CI 1.104–6.268, P = 0.029), higher tumor stage (HR = 2.506, 95% CI 1.026–6.122, P = 0.044), higher N stage (HR = 3.789, 95% CI 1.507–9.527, P = 0.005) and overlapped tumor location (HR = 4.543, 95% CI 1.089–18.948, P = 0.038). Also, patients with gene rearrangements was adverse prognosis factor for PC GC patients, although without significant difference (HR = 2.384, 95% CI 0.993–5.723, P = 0.052). Results of multivariate Cox regression suggested that among PC GC patients, age over 60 years old (HR = 3.083, 95% CI 1.114–8.531, P = 0.030) were considered as adverse prognosis factor. In addition, Cox’s regression model was separately used to estimate HR and 95% CI in each subgroup (Fig. 2b). Among IIIA-B stage (HR = 2.64, 95% CI 1.03–6.78, P = 0.043), PD-L1 positive (HR = 4.74, 95% CI 1.04–21.63, P = 0.045) PC GC patients, gene rearrangement was a negative factor for overall survival (Fig. 2b).

Table 2 Clinical characteristics of PC GC with and without gene rearrangements
Fig. 2
figure 2

a Kaplan–Meier estimates of survival probability. The survival curve of patients with and without rearrangements. b Subgroup analysis of PC GC patients with and without rearrangements

Function of TACC2-FGFR2 fusion in PC GC

Fluorescence in situ hybridization (FISH) and RNA sequencing (RNA-seq) was performed in two samples with FGFR2 rearrangements (FGFR2/VTI1A and FGFR2/TACC2). FGFR2/VTI1A and FGFR2/TACC2 rearrangements could both be detected by FISH in corresponding patient’s samples (Additional file 1: Figure S2). TACC2-FGFR2 fusion was verified in the form of TACC2 (exon1–2) -FGFR2 (exon5–18) by RNA-seq (Fig. 3a, Additional file 1: Figure S3). However, no RNA product of FGFR2-VTI1A rearrangement was detected by RNA-seq. We presumed that it might be due to no RNA product was transcribed by FGFR2-VTI1A rearrangement indeed. Next, we evaluated the expression level of FGFR2 protein in patient’s surgical samples with TACC2-FGFR2 using immunohistochemistry (IHC), finding increased FGFR2 expression in tumor area compared to adjacent normal surface epithelial area (Fig. 3b).

Fig. 3
figure 3

a Illustration of breakpoint of TACC2 and FGFR2. Exons (Ex) of TACC2 and FGFR2 are indicated with red and blue, respectively. b Representative images of FGFR2 staining for PC GC patients with TACC2-FGFR2 rearrangement with tumor area (left), adjacent normal surface epithelial area (right). Scale bar = 500 µm

To further investigate TACC2-FGFR2 fusion in PC GC, we stably expressed TACC2-FGFR2 in gastric cancer cell lines MKN45 and NUGC4. Using qRT-PCR, we found FGFR2 mRNA levels were increased in TACC2-FGFR2-expressing MKN45 and NUGC4 cells (Fig. 4a). Moreover, IHC showed TACC2-FGFR2 upregulated FGFR2 protein expression in TACC2-FGFR2-expressing MKN45 and NUGC4 cells. (Fig. 4b).

Fig. 4
figure 4

a qRT-PCR for the TACC2-FGFR2 fusion transcript in MKN45, NUGC4 cells and corresponding TACC2-FGFR2-expressing cells. Data are presented as mean ± SEM. * means P < 0.05, ** means P < 0.01. b IHC of MKN45, NUGC4 cells and corresponding TACC2-FGFR2-expressing cells for FGFR2 protein. Scale bar = 50 µm. MKN45T: TACC2-FGFR2-expression MKN45 cells. NUGC4T: TACC2-FGFR2-expression NUGC4 cells. c Sensitivity of MKN45, NUGC4 cells transfected with TACC2-FGFR2 or control plasmids to FGFR2 inhibitors, including BGJ398, AZD4547 and Erdafitinib. MKN45T: TACC2-FGFR2-expression MKN45 cells. NUGC4T: TACC2-FGFR2-expression NUGC4 cells

To figure out the role of TACC2-FGFR2 fusion in targeted therapy for GC, we treated MKN45, NUGC4 cells and TACC2-FGFR2-expressing MKN45, NUGC4 cells with FGFR2 inhibitors, including BGJ398, AZD4547 and Erdafitinib. TACC2-FGFR2-expressing MKN45 and NUGC4 cells are more sensitive to all these three FGFR2 inhibitors (Fig. 4c).


GC is a phenotypically and molecularly highly heterogeneous disease. Intratumoral, intrapatient and interpatient heterogeneity in GC remains a crucial barrier for targeted therapies [2]. PC GC is a unique subtype of GC, tending to metastasis and with poor prognosis [13, 14]. None of current therapies showed satisfying results [4]. Therefore, there is a critical need to develop new efficacious therapeutic agents for PC GC. Molecular characteristics are becoming more and more important for GC treatment. Several molecular GC classification systems have been proposed these years for better clinical treatments [8, 9]. A few papers have focused on genomic alterations of PC GC and presented significantly mutated genes identified are TP53, APC, KIT, EGFR, PIK3CA, CTNNB1, ARID1A, and CDH1 [13, 15,16,17,18]. Our results showed the top 10 most frequent altered genes among PC GC were TP53 (48%), CDH1 (31%), ARID1A (14%), FGFR2 (14%), ERBB2 (9%), CDKN2A (9%), FGF3 (8%), LRP1B (9%), FGF19 (8%) and FGF4 (8%), consistent with previous research.

However, these molecular characteristics of PC GC patients are still unclear for treatment and prognosis. To better understand the molecular characteristics of PC GC, we respectively analyzed SNVs and INDELs, CNVs and gene fusions and rearrangements. We found that 20% (13/64) PC GC patients harboring somatic gene rearrangements. And, patients with rearrangements (n = 9) had a shorter overall survival (OS) in comparison with patients without any gene rearrangement (n = 19) (16.0 months vs 21.0 months, P = 0.043) (Fig. 3b). It may owe to gene rearrangements could form severe cancer driving structural variants (SV), including insertions, deletions, tandem duplications, inversions, translocations, and more complex rearrangements [19]. This is an indication that gene rearrangements play an important role in PC GC development and prognosis. Gene rearrangement might be an adverse prognostic factor for PC GC patients and more effective therapies targeting gene rearrangements should be studied for PC GC.

FGFR2, known as fibroblast growth factor receptor-2, is a transmembrane tyrosine kinase receptor, regulating cell proliferation, survival, migration and angiogenesis [20]. Genetic alterations in FGFR2, including gene amplification, mutations or rearrangements may dysregulate the FGF signaling pathway, influence the development and progression of various cancers by activating the downstream PI3K–AKT and MAPK–ERK pathways [21]. Previous study demonstrated that FGFR2 overexpression, mainly due to FGFR2 gene amplification, is associated with poor pathological features, including deeper tumor invasion, more LN metastasis, advanced tumor stage, and worse survival in GC [22]. And, many researches indicated that the incidence of FGFR2 overexpression might differ between histological subtypes according to Lauren’s classification [21]. Hattori found FGFR2 overexpression in 52.6% (20/38) diffuse-type GCs, but in none of 11 intestinal-type GCs [23]. PC GC tend to be diffuse-type according to Lauren’s classification, however, no study verified the situation of FGFR2 genomic alterations in PC GC. Our results firstly showed that FGFR2 is more frequently mutated in PC GC than non-PC GC (14% vs. 6%, P = 0.037), including 12.5% CNVs. Several small-molecule inhibitors and antibodies for FGFR2 are under clinical trials [24, 25]. Recently, Catenacci [25] verified bemarituzumab, an IgG1 antibody specific for the FGFR2b receptor, seemed to be well tolerated and demonstrated single-agent activity as lateline therapy in patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma (GEA). Moreover, bemarituzumab is currently being evaluated in combination with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing advanced-stage GEA. Preliminary results showed that bemarituzumab, added to mFOLFOX6 chemotherapy, led to clinically meaningful and statistically significant improvements in PFS (9.5 m vs. 7.4 m, P = 0.0727), OS (not reach vs. 12.9 m, P = 0.0268) and ORR (47% vs. 33%). And, the higher the FGFR2 expression, the better the prognosis [24]. FGFR2 inhibitors may be a good choice for PC GC with FGFR2 CNVs.

In addition, PC GC patients not only have more FGFR2 CNVs, but also have recurrent FGFR2 rearrangement (FGFR2/VTI1A and FGFR2/TACC2) in our study. FGFR rearrangements present in 13% to 17% of intrahepatic cholangiocarcinoma and represent driver mutations [26]. Several pre-clinical studies and clinical trials have demonstrated that FGFR2 rearrangements in cholangiocarcinoma can predict tumor sensitivity to FGFR2 inhibitors and become an important therapy in these highly selected patients [27,28,29]. To verify whether FGFR2 rearrangements can be a marker for targeted therapy in PC GC patients, we transfected TACC2-FGFR2 construct into GC cell lines (MKN45 and NUGC4), which has not been studied in PC GC before. We chose FGFR2 inhibitors, including AZD4547, Erdafitinib, and BGJ398 to treat GC cell lines with or without TACC2-FGFR2 fusion, and got similar results. Recently, many FGFR2 inhibitors are in the pipeline, these three drugs belonged to the first FGFR2 inhibitors studied. AZD4547 has been used in clinical trials of gastric adenocarcinoma [30], and Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) [31] and BGJ398 (Infigratinib) [27, 32] was or will be approved by FDA for treatment of tumor with FGFR2 alterations. Our results firstly verified that the FGFR2 mRNA and protein expression level (Fig. 4b, c) were increased in GC cells with FGFR2 rearrangement and cells became more sensitive to FGFR2 inhibitors.


In conclusion, we firstly identified FGFR2 alteration was more frequently among PC GC than non-PC GC, including CNVs and rearrangements. Moreover, we verified TACC2-FGFR2 fusion could increase FGFR2 expression in mRNA and protein level, and GC cell lines with TACC2-FGFR2 fusion were more sensitive to FGFR2 inhibitors. All these results suggested that FGFR2 may be a potential therapeutic target for PC GC.

Availability of data and materials

The data described in this manuscript are contained in published articles or available from the corresponding author upon reasonable request.



American Joint Committee on Cancer


Cell counting kit-8


Chromosomal instability


Copy number variants


Epstein–Barr virus


Formalin fixed paraffin embedded


Fluorescence in situ hybridization


Gastric cancer


Gastroesophageal junction adenocarcinoma


Genomically stable




Short and long insertions/deletions


Mismatch repair


Microsatellite instability


Microsatellite instability-high


Next-generation sequencing


Overall survival


Poorly cohesive


Quantitative real time polymerase chain reaction


RNA sequencing


Single nucleotide variants


Structural variants


The Cancer Genome Atlas


Tumor mutation burden


Tumor mutational burden-high


Tumor mutational burden-low


Tumor protein 53


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. The Lancet. 2020;396:635–48.

    Article  CAS  Google Scholar 

  3. Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.

    Article  CAS  Google Scholar 

  4. Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, et al. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19:494.

    Article  Google Scholar 

  5. Sarriugarte Lasarte A, GarcIa Alberdi E, Martinez Indart L, Gutierrez Grijalba O, Albarez Abad I, Guerra Lerma M, et al. “From Lauren’s diffuse gastric cancer to WHO’s poorly cohesive carcinoma.” Clinicopathological and prognostic characteristics. Rev Esp Enferm Dig. 2020;113:324–32.

    Google Scholar 

  6. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141:476–85, 85 e1–11.

  7. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554–65.

    Article  CAS  Google Scholar 

  8. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article  Google Scholar 

  9. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.

    Article  CAS  Google Scholar 

  10. Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. J Pathol. 2020;250:19–29.

    Article  CAS  Google Scholar 

  11. Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33:3140–1.

    Article  CAS  Google Scholar 

  12. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31.

    Article  Google Scholar 

  13. Huang KH, Chen MH, Fang WL, Lin CH, Chao Y, Lo SS, et al. The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers (Basel). 2020;12:2318.

    Article  CAS  Google Scholar 

  14. Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer. 2017;20:591–601.

    Article  CAS  Google Scholar 

  15. Shu Y, Zhang W, Hou Q, Zhao L, Zhang S, Zhou J, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nat Commun. 2018;9:2447.

    Article  Google Scholar 

  16. Xu B, Liu F, Liu Q, Shi T, Wang Z, Wu N, et al. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J Gastrointest Oncol. 2020;11:1431–9.

    Article  Google Scholar 

  17. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573–82.

    Article  CAS  Google Scholar 

  18. Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.

    Article  Google Scholar 

  19. Yang L, Luquette LJ, Gehlenborg N, Xi R, Haseley PS, Hsieh CH, et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell. 2013;153:919–29.

    Article  CAS  Google Scholar 

  20. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.

    Article  CAS  Google Scholar 

  21. Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol. 2016;29:1095–103.

    Article  CAS  Google Scholar 

  22. Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: a meta-analysis. J Cancer. 2019;10:20–7.

    Article  CAS  Google Scholar 

  23. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996;2:1373–81.

    CAS  PubMed  Google Scholar 

  24. Wainberg ZA, Enzinger PC, Kang Y-K, Yamaguchi K, Qin S, Lee K-W, Oh SC, Li J, Turk HM. A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT). In: ASCO gastrointestinal cancer symposium. 2021;LBA160.

  25. Catenacci DVT, Rasco D, Lee J, Rha SY, Lee K-W, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38:2418–26.

    Article  CAS  Google Scholar 

  26. Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630–8.

    Article  CAS  Google Scholar 

  27. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276–82.

    Article  CAS  Google Scholar 

  28. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235–42.

    Article  CAS  Google Scholar 

  29. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;19:2878–80.

    Article  CAS  Google Scholar 

  30. Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28:1316–24.

    Article  Google Scholar 

  31. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–48.

    Article  CAS  Google Scholar 

  32. Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35:157–65.

    Article  CAS  Google Scholar 

Download references


The authors would like to thank all patients who participated in this study.


This work was funded by Grants from National Natural Science Foundation of China (82073382) and the Distinguished Young Scholars of Jiangsu Province (BK20190001). The funding sources had no role in the study design, data collection, data analysis, data interpretation, or writing of this review. The funding sources have no involvement in study design; the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Author information

Authors and Affiliations



YW: Drafting the article; TS: Revising it critically for important intellectual content; XW: The acquisition of data; JH: Visualization; LY: Analysis and interpretation of data; QL: The acquisition of data; NW: Analysis and interpretation of data; BL: Supervision, final approval of the version to be submitted; JW: Conceptualization, funding acquisition. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jia Wei.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki) and approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2016-196-01).

Consent for publication

Not applicable.

Competing interests

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Schema diagram of NGS process. NGS next generation sequencing. Table S1. Univariate and multivariate analyses for PC GC patients. Figure S2. FISH detection of the FGFR2 fusion. Yellow arrows indicate separate location of different FGFR2 exons (red and green). Scale bar = 5 µm. Figure S3. RNA-sequence reads map of TACC2-FGFR.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Shi, T., Wang, X. et al. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma. J Transl Med 19, 401 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: